LeonaBio, Inc. Common Stock LONA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Excluding Stockbased Or Depreciation Expense by Product | ||||||
| ATH-1020 | $0-100% | —— | —— | —— | $5K-93.9% | |
| ATH-1105 | $243K-73.7% | $581K-67.2% | $673K-72.4% | $1.24M-62.3% | $924K-14.1% | |
| Fosgonimeton ATH-1017 | $183K-86.0% | $155K-96.0% | $317K-96.9% | $555K-95.8% | $1.31M-90.8% | |
| Lasofoxifene | $8.63M— | —— | —— | —— | $0— | |
| Milestone Liability | -$929K— | —— | —— | —— | $0— | |
| Personnel-Related Costs Excluding Stock-Based Compensation | $1.5M+49.8% | $1.41M-39.3% | $895K-71.9% | $918K-71.0% | $998K-72.5% | |
| Preclinical Programs And Other Costs | $355K-11.9% | $323K-30.2% | $268K-69.2% | $258K-72.8% | $403K-81.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LeonaBio, Inc. Common Stock break its business down?
- LeonaBio, Inc. Common Stock (LONA) reports research and development expense excluding stockbased or depreciation expense by product across 8 parts — Acquired In Process Research And Development, ATH-1020, ATH-1105, Fosgonimeton ATH-1017 and Lasofoxifene. Each is extracted from the segment footnotes and tracked over time.
- Where does LeonaBio, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LeonaBio, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.